Clinical Trials of High-intensity Focused Ultrasound for Cancer: Concerns Arising from Low Post-Hoc Power
- PMID: 38323616
- DOI: 10.2174/0109298673281773240104142757
Clinical Trials of High-intensity Focused Ultrasound for Cancer: Concerns Arising from Low Post-Hoc Power
Abstract
Prospective controlled trials of high-intensity focused ultrasound (HIFU) for cancers were evaluated. Post-hoc power was <0.80 in 30/46 trials and in 22/38 trials with positive results, indicating low quality in most trials. Unscientific endpoints, small sample sizes, and high dropout rates led to low post-hoc power that caused inter-trial heterogeneity and overestimated the therapeutic effect. The objective response rate was not a substitute for survival time for estimating the sample size and assessing the efficacy. The present data can interpret a paradox: HIFU is considered to have slighter cytotoxicity to noncancer tissues and no radiation but is frequently combined with chemotherapy and/or radiotherapy in practice.
Keywords: High-intensity focused ultrasound; cancer clinical trial; combination therapy; data quality; overestimation.; post-hoc power.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
References
-
- Onwuegbuzie A.J.; Leech N.L.; Post hoc power: A concept whose time has come. Underst Stat 2004,3(4),201-230 - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical